CYP1A1 polymorphisms and lung cancer risk: A meta-analysis

Pharmacogenetics

Volumn 10, Issue 2, 2000, Pages 105-114

  Houlston, R S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CYP1A1; Lung cancer; Meta analysis; Polymorphism

Indexed keywords

CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 ISOENZYME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; META ANALYSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; STATISTICS;

EID: 0034070148     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200003000-00002     Document Type: Article

References (49)

1. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15:1785-1790.
2. Bouchardy C, Wikman H, Benhamou S, Hirvonen A, Dayer P, Husgafvel-Pursiainen K. CYP1A1 genetic polymorphisms, tobacco smoking in a French Caucasian population. Biomarkers 1997; 2:131-134.
3. Cascorbi, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56:4965-4969.
4. Daly AK, Fairbrother KS, Smart J. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol Lett 1998; 102-103:143-147.
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7:177-188.
6. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidmiol Rev 1992; 4:154-176.
7. Doll R, Peto R. The cause of cancer. Oxford: Oxford University Press; 1981. p. 1221.
8. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889A to G), and T to C mutation in the 3′-flanking region. Clin Invest 1994; 72:240-248.
9. Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer, the Mayo lung project revisited. Cancer 1993; 72:1573-1580.
10. Fleiss JL, Tytun A, Uray HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 1980; 36:343-346.
11. Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 1997; 8:544-553.
12. Hamada G, Sugimura H. Kiyoko K, Kiyokawa E, Iwase T, Tanaka M, et al. The heme-binding region polymorphism of cytochrome P450IA1 (Cyp1A1), rather than the RsaI polymorphism of IIE1 (cypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomarker Prev 1995; 4:63-67.
13. Hayashi S, Watanabe J, Nakachi K, Kawijiri K. Genetic linkage of lung cancer associated MspI polymorphism with amino acid replacement in the heme binding region of the human cytochrome-P450A1 gene. J Biochem 1991; 110:407-411.
14. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992; 83:866-870.
15. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Inter-individual differences in expression of human Ah receptor and related P450 genes. Carcinogenesis 1994; 15:801-806.
16. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992a; 1:485-489.
17. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Sorsa M, Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 1992b; 2:259-263.
18. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ Health Persp Suppl 1993; 101:109-112.
19. Houlston RS and Peto J. Genetics of common cancers. In: Eeles RA, Ponder B, Easton DE, Horwich A, editors. Inherited predisposition to cancer. London: Chapman & Hall; 1996. pp. 208-226.
20. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Vols 1-42. Lyon, France: International Agency for Research on Cancer; 1987.
21. Ishibe N, Wiencke JK, Zuo Z-F, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 1997; 6:1075-1080.
22. Jacquet M, Lambert V, Muller M, Kremers P, Gielen J. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence. Eur J Cancer 1996; 32A:1701-1706.
23. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS 1990; 1:131-133.
24. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Haematol 1993a; 14:77-87.
25. Kawajiri K, Nakachi K, Imai K, Watanabe J. Hayashi SI. Germline polymorphisms of the p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993b; 14:1085-1089.
26. Kawajiri K, Eguchi H, Nakachi K, Sekiyu T, Yamamoto M. Association of CYP1A1 germline polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56:72-76.
27. Kihara M, Kihara M, Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 1995; 16:2331-2336.
28. Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996; 87:18-24.
29. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between acyl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreseved lymphocytes. Cancer Res 1982; 42:5030-5037.
30. Le Marchand L, Sivaraman L, Pierce L, Seifred A, Lum A, Wilkins LR, Lau AF. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1988; 58:4858-4863.
31. McLemore TL, Adelberg S. Liu MC, McMahon NA, Yu SJ, Hubbard WC, et al. Expresssion of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for pulmonary carcinomas. J Natl Cancer Inst 1990; 82:1333-1339.
32. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics 1998; 7:303-307.
33. Nakachi K, Imai K, Watanabe J, Hayashi S-I, Kawajiri K. Genetic susceptibility squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51:5177-5180.
34. Nakachi K, Imai K, Watanabe J, Hayashi S-I, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53:2994-2999.
35. Ohshima S, Xu Y. p53 gene mutations, and CYP1A1 and GSTM1 genotypes in pulmonary squamous cell carcinomas. Mol Pathol 1997; 50:108-110.
36. Persson I, Johansson I, Ingelman-Sundberg MI. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with inter-individual differences in cancer susceptibility. Biochem Biophy Res Com 1997; 231:227-230.
37. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomised controlled trials. N Engl J Med 1987; 316:450-455.
38. Shields PG, Caporosa N, Falk R, Sugimura H, Rivers CE, Trump BF, et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarker Prev 1993; 2:481-485.
39. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25:27-65.
40. Strauss GM. Measuring effectiveness of lung cancer screening: from consensus to controversy and back. Chest 1997; 112 (Suppl. 4):216S-228S.
41. Sugimura H, Suzuki I, Hamada GS, Iwase T, Takahashi T, Nagura K, et al. Cytochrome P-450IA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarker Prev 1994; 3:145-148.
42. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kimo I, Tsugane S. CYP1A1 and CYP2E1 polymorphism lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 1995; 5:S145-S148.
43. Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K, et al. Association of the Ile462Val (exon7) polymorphism of the cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarker Prev 1998; 7:413-417.
44. Taioli E, Ford J, Trachman J, Li Y, Demooulos R, Garte S. Lung cancer risk and CYP1A1 in African Americans. Carcinogenesis 1998; 19:813-817.
45. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL. Human CYP1A1 (cytochrome P450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1:20-25.
46. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994; 4:104-106.
47. Xie X, Ott J. Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet 1993; 53:1107.
48. Xu X, Kelsey KT, Wienke JK, Wain JC, Christani DC. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarker Prev 1996; 5:687-692.
49. Zhang Z, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterisation of purified human recombinant cytochrome P450A1-Ile 462 and -Val 462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996; 56:3926-3933.